Effects of poly(Ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and rantes release in vitro

Shinobu Wakamoto, Mitsuhiro Fujihara, Hideki Abe, Hiromi Sakai, Shinji Takeoka, Eishun Tsuchida, Hisami Ikeda, Kenji Ikebuchi

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    We studied the effects of hemoglobin-vesicles modified with PEG (PEG-HbV), a type of liposome-encapsulated hemoglobin (LEH), on human platelet functions in vitro. The effect of a low concentration of PEG-HbV (Hb; 5.8 mg/dl) was assessed by examining an agonist-induced aggregation response, and that of relatively high concentrations of PEG-HbV (Hb; 0.29, 1 and 2 g/dl) by measuring the release of RANTES (Regulated upon activation, normal T-cell expressed and presumably secreted) from platelets, which is regarded as a marker of platelet activation. The preincubation of platelets with PEG-HbV at 5.8 mg/dl of Hb did not affect platelet aggregation induced by collagen, thrombin and ristocetin. The pretreatment of platelet-rich plasma (PRP) with PEG-HbV at concentrations up to 2 g/dl of Hb had no aberrant effects on the collagen-induced RANTES release. Furthermore, the collagen-induced release of RANTES from PRP was not affected by longer incubation with PEG-HbV at 2 g/dl of Hb. The basal levels of RANTES from PRP were unchanged in the presence of PEG-HbV. These results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on platelet functions in the presence of plasma.

    Original languageEnglish
    Pages (from-to)191-201
    Number of pages11
    JournalArtificial Cells, Blood Substitutes, and Immobilization Biotechnology
    Volume29
    Issue number3
    DOIs
    Publication statusPublished - 2001

    Fingerprint

    Hemoglobin
    Platelets
    Platelet Aggregation
    Polyethylene glycols
    Platelet-Rich Plasma
    Hemoglobins
    Blood Platelets
    Agglomeration
    T-Lymphocytes
    Collagen
    T-cells
    Chemical activation
    Ristocetin
    Plasmas
    Platelet Activation
    Liposomes
    Thrombin
    In Vitro Techniques
    PEG-hemoglobin

    ASJC Scopus subject areas

    • Biomedical Engineering
    • Hematology
    • Biotechnology
    • Biomaterials

    Cite this

    Effects of poly(Ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and rantes release in vitro. / Wakamoto, Shinobu; Fujihara, Mitsuhiro; Abe, Hideki; Sakai, Hiromi; Takeoka, Shinji; Tsuchida, Eishun; Ikeda, Hisami; Ikebuchi, Kenji.

    In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology, Vol. 29, No. 3, 2001, p. 191-201.

    Research output: Contribution to journalArticle

    Wakamoto, Shinobu ; Fujihara, Mitsuhiro ; Abe, Hideki ; Sakai, Hiromi ; Takeoka, Shinji ; Tsuchida, Eishun ; Ikeda, Hisami ; Ikebuchi, Kenji. / Effects of poly(Ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and rantes release in vitro. In: Artificial Cells, Blood Substitutes, and Immobilization Biotechnology. 2001 ; Vol. 29, No. 3. pp. 191-201.
    @article{cf9addf2d0e3457ba0e2a58adb8fc4a4,
    title = "Effects of poly(Ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and rantes release in vitro",
    abstract = "We studied the effects of hemoglobin-vesicles modified with PEG (PEG-HbV), a type of liposome-encapsulated hemoglobin (LEH), on human platelet functions in vitro. The effect of a low concentration of PEG-HbV (Hb; 5.8 mg/dl) was assessed by examining an agonist-induced aggregation response, and that of relatively high concentrations of PEG-HbV (Hb; 0.29, 1 and 2 g/dl) by measuring the release of RANTES (Regulated upon activation, normal T-cell expressed and presumably secreted) from platelets, which is regarded as a marker of platelet activation. The preincubation of platelets with PEG-HbV at 5.8 mg/dl of Hb did not affect platelet aggregation induced by collagen, thrombin and ristocetin. The pretreatment of platelet-rich plasma (PRP) with PEG-HbV at concentrations up to 2 g/dl of Hb had no aberrant effects on the collagen-induced RANTES release. Furthermore, the collagen-induced release of RANTES from PRP was not affected by longer incubation with PEG-HbV at 2 g/dl of Hb. The basal levels of RANTES from PRP were unchanged in the presence of PEG-HbV. These results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on platelet functions in the presence of plasma.",
    author = "Shinobu Wakamoto and Mitsuhiro Fujihara and Hideki Abe and Hiromi Sakai and Shinji Takeoka and Eishun Tsuchida and Hisami Ikeda and Kenji Ikebuchi",
    year = "2001",
    doi = "10.1081/BIO-100103043",
    language = "English",
    volume = "29",
    pages = "191--201",
    journal = "Artificial Cells, Nanomedicine and Biotechnology",
    issn = "2169-1401",
    publisher = "Informa Healthcare",
    number = "3",

    }

    TY - JOUR

    T1 - Effects of poly(Ethyleneglycol)-modified hemoglobin vesicles on agonist-induced platelet aggregation and rantes release in vitro

    AU - Wakamoto, Shinobu

    AU - Fujihara, Mitsuhiro

    AU - Abe, Hideki

    AU - Sakai, Hiromi

    AU - Takeoka, Shinji

    AU - Tsuchida, Eishun

    AU - Ikeda, Hisami

    AU - Ikebuchi, Kenji

    PY - 2001

    Y1 - 2001

    N2 - We studied the effects of hemoglobin-vesicles modified with PEG (PEG-HbV), a type of liposome-encapsulated hemoglobin (LEH), on human platelet functions in vitro. The effect of a low concentration of PEG-HbV (Hb; 5.8 mg/dl) was assessed by examining an agonist-induced aggregation response, and that of relatively high concentrations of PEG-HbV (Hb; 0.29, 1 and 2 g/dl) by measuring the release of RANTES (Regulated upon activation, normal T-cell expressed and presumably secreted) from platelets, which is regarded as a marker of platelet activation. The preincubation of platelets with PEG-HbV at 5.8 mg/dl of Hb did not affect platelet aggregation induced by collagen, thrombin and ristocetin. The pretreatment of platelet-rich plasma (PRP) with PEG-HbV at concentrations up to 2 g/dl of Hb had no aberrant effects on the collagen-induced RANTES release. Furthermore, the collagen-induced release of RANTES from PRP was not affected by longer incubation with PEG-HbV at 2 g/dl of Hb. The basal levels of RANTES from PRP were unchanged in the presence of PEG-HbV. These results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on platelet functions in the presence of plasma.

    AB - We studied the effects of hemoglobin-vesicles modified with PEG (PEG-HbV), a type of liposome-encapsulated hemoglobin (LEH), on human platelet functions in vitro. The effect of a low concentration of PEG-HbV (Hb; 5.8 mg/dl) was assessed by examining an agonist-induced aggregation response, and that of relatively high concentrations of PEG-HbV (Hb; 0.29, 1 and 2 g/dl) by measuring the release of RANTES (Regulated upon activation, normal T-cell expressed and presumably secreted) from platelets, which is regarded as a marker of platelet activation. The preincubation of platelets with PEG-HbV at 5.8 mg/dl of Hb did not affect platelet aggregation induced by collagen, thrombin and ristocetin. The pretreatment of platelet-rich plasma (PRP) with PEG-HbV at concentrations up to 2 g/dl of Hb had no aberrant effects on the collagen-induced RANTES release. Furthermore, the collagen-induced release of RANTES from PRP was not affected by longer incubation with PEG-HbV at 2 g/dl of Hb. The basal levels of RANTES from PRP were unchanged in the presence of PEG-HbV. These results suggest that PEG-HbV, at the concentrations studied, have no aberrant effects on platelet functions in the presence of plasma.

    UR - http://www.scopus.com/inward/record.url?scp=0035024891&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0035024891&partnerID=8YFLogxK

    U2 - 10.1081/BIO-100103043

    DO - 10.1081/BIO-100103043

    M3 - Article

    C2 - 11358035

    AN - SCOPUS:0035024891

    VL - 29

    SP - 191

    EP - 201

    JO - Artificial Cells, Nanomedicine and Biotechnology

    JF - Artificial Cells, Nanomedicine and Biotechnology

    SN - 2169-1401

    IS - 3

    ER -